GlaxoSmithKline (GSK) and Genmab’s antibody Arzerra, which has been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will be manufactured by Lonza.
Under agreements with GSK and Genmab, Lonza carried out a program of process development and cGMP manufacturing services to support the licensure. Lonza will supply Arzerra drug substance to GSK under the terms of a long-term supply agreement. Financial details of the agreement were not disclosed.
Stephan Kutzer, COO of custom manufacturing APIs at Lonza, said: “We are looking forward to a long-term relationship between Lonza and GSK. We expect that ArzerraTM will be a key biopharmaceutical for both companies, and we are proud that we could bring together the expertise of both companies to develop a state-of-the-art manufacturing process.”